首页> 外文期刊>Nephron >Adequate seroresponse to influenza vaccination in dialysis patients.
【24h】

Adequate seroresponse to influenza vaccination in dialysis patients.

机译:透析患者对流感疫苗有足够的血清反应。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Hemodialysis (HD) patients are immunocompromised, and they have been shown to react suboptimally to recommended vaccinations. Advances in dialysis therapy and other supportive measures may theoretically result in better immune system functions. Clinical evidence supporting this theory has, however, not been presented. With influenza vaccination response, we tried to address this question. METHODS: 42 HD and 15 continuous ambulatory peritoneal dialysis (CAPD) patients were vaccinated with a trivalent influenza vaccine, and the seroresponses at 5 weeks were measured. The results were compared with those of similarly vaccinated 20 nephrology outpatient clinic patients with varying degrees of renal insufficiency and those of 31 cardiac patients with normal renal function. RESULTS: The dialysis patients had higher prevaccination titers of hemagglutination-inhibiting (HI) antibodies to all three vaccine virus antigens than the other groups due to more frequent previous vaccinations. The dialysis patients exhibited lower antibody increases, but an almost comparable proportion of them reached a protective antibody level (HI titers > or =40) 5 weeks after vaccination [A/H3N2: 61% (cardiac patients), 35% (nephrology outpatient clinic patients), 67% (CAPD), and 36% (HD); A/H1N1: 71, 70, 80 and 60; B: 97, 90, 80, and 76%, respectively]. Among the HD group, all patients receiving parenteral calcitriol except 1 (83%), but only 50% of the other HD patients produced protective antibody titers at least to two out of three vaccine virus antigens. No other patient- or HD treatment-associated parameter was significantly related to the vaccination-induced antibody response. CONCLUSIONS: We conclude that influenza vaccination of dialysis patients according to current recommendations may be effective. Additionally, our results suggest that parenteral calcitriol treatment may augment the immune response of HD patients even in a clinically relevant way, an effect so far shown only in in vitro studies. Copyright 2000 S. Karger AG, Basel
机译:背景:血液透析(HD)患者免疫功能低下,已被证明对推荐的疫苗反应欠佳。从理论上讲,透析治疗和其他支持措施的进步可能会改善免疫系统的功能。但是,尚未提供支持该理论的临床证据。通过应对流感疫苗,我们试图解决这个问题。方法:对42例HD和15例连续性非卧床腹膜透析(CAPD)患者接种三价流感疫苗,并测量5周时的血清反应。将结果与同样接种了20例不同程度肾功能不全的肾脏病门诊患者和31例肾功能正常的心脏病患者的结果进行了比较。结果:透析患者对所有三种疫苗病毒抗原的血凝抑制(HI)抗体的疫苗接种前效价高于其他人群,因为以前的疫苗接种频率更高。透析患者的抗体升高较低,但几乎有相当比例的患者在接种疫苗后5周达到保护性抗体水平(HI滴度>或= 40)[A / H3N2:61%(心脏病患者),35%(肾脏病门诊)患者),67%(CAPD)和36%(HD); A / H1N1:71、70、80和60; B:分别为97%,90%,80%和76%]。在HD组中,除1例(83%)外,所有接受肠胃外降钙三醇的患者,但其他HD患者中只有50%产生了至少三种疫苗病毒抗原中的两种的保护性抗体滴度。没有其他与患者或HD治疗相关的参数与疫苗诱导的抗体反应显着相关。结论:我们得出结论,根据当前建议对透析患者进行流感疫苗接种可能是有效的。此外,我们的研究结果表明,肠胃外钙三醇治疗可能甚至以临床相关的方式增强HD患者的免疫反应,这一效果目前仅在体外研究中显示。版权所有2000 S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号